References
- Jacquet L. Prurigos d'E Besnier. In: Besnier E, Brocq L, Lacquet L, eds. La pratique dermatologique. Paris: Masson, 1904: 62
- Hanifin JM, Rajka G. The diagnostic features of atopic dermatitis. Acta Venereol (Stockh) Suppl 1980; 92: 44–7
- Leung DY. Atopic dermatitis: immunobiology and treatment with immune modulators. Clin Exp Immunol 1997; 107(suppl 1): 25–30
- Laughter D, Istvan JA, Tofte SJ, et al. The prevalence of atopic dermatitis in Oregon school children. J Am Acad Dermatol 2000; 43(4): 649–55
- Larsen FS, Holm NV, Henningsen K. Atopic dermatitis: a genetic-epidemiologic study in a population-based twin sample. J Am Acad Dermatol 1986; 15(3): 487–94
- Smith EW. Four decades of topical corticosteroid assessment. Curr Probl Dermatol 1995; 22: 124–31
- Lubach D, Rath J, Kietzmann M. Skin atrophy induced by initial continuous topical application of clobetasol followed by intermittent application. Dermatology 1995; 190(1): 51–5
- Pierard GE, Pierard-Franchimont C, Ben Mosbah T, et al. Adverse effects of topical corticosteroids. Acta Derm Venereol Suppl (Stockh) 1989; 151: 26–30
- Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol 2002; 46(2): 228–41
- Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46(4): 495–504
- Paller A, Eichenfield LF, Leung DY, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001; 44(1 suppl): S47–57
- Kapp A, Papp K, Bingham A, et al. Long- term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid antiinflammatory drug. J Allergy Clin Immunol 2002; 110(2): 277–84